Home / News / India News / Article /
Brazilian regulator says Bharat Biotech's Covaxin manufacturing facility fails to meet CGMP standards
Updated On: 31 March, 2021 12:00 AM IST | Hyderabad | PTI
The Hyderabad-based vaccine maker said it is working towards resolving the issues cited during the inspection and the order of 20 million doses from the Brazilian government is still active

Photo for representational purpose
The Brazilian health regulator Anvisa has denied permission to import Bharat Biotech's COVID-19 vaccine Covaxin into the country after its authorities found that the plant in which the vaccine is being made did not meet the Current Good Manufacturing Practice (CGMP) requirements.
Reacting to it, the Hyderabad-based vaccine maker said it is working towards resolving the issues cited during the inspection and the order of 20 million doses from the Brazilian government is still active.
How do you like the new new mid-day.com experience? Share your feedback and help us improve.

